10-20% of patients with relapsed and refractory MM 4 , and losses of ATM and ATR are even rarer 5 .
a r t i c l e s In epithelial cancers, rampant DNA double-strand break (DSB) formation followed by activation of the DNA damage response (DDR) occurs in both premalignant and malignant conditions. However, in precancerous settings, senescence and apoptotic responses, comprising the so-called 'tumorigenesis barrier' , prevent progression to malignancy 1 until the tumor suppressor TP53 (p53) is inactivated, thereby triggering genomic instability and enhancing tumor cell growth.
Variable levels of γ-H2A.X and phosphorylated ATM (pATM) have been reported in acute myeloid leukemia (AML), myelodysplastic syndromes 2 and multiple myeloma (MM) 3 . However, in blood tumors, the presence and functional role of ongoing DNA damage in carcinogenesis have not been explored in detail. Additionally, inactivation of p53 does not appear to be a pivotal event in the evolution from premalignancy toward cancer in these diseases, as p53 mutations are relatively rare and appear late during the evolution of these tumors. For example, p53 mutations and deletions are rare in patients with newly diagnosed MM (5-10%) and are present in only a r t i c l e s 6 0 0 VOLUME 20 | NUMBER 6 | JUNE 2014 nature medicine
RESULTS

MM cells evade apoptosis despite pervasive DNA damage
We first explored a panel of MM cell lines and primary MM cells to confirm the presence of widespread DNA damage 3 . Eleven of 13 MM cell lines, as well as primary cells derived from five subjects with MM, showed high γ-H2A.X staining (Fig. 1a,b and Supplementary  Fig. 1a,b) and an activated DDR ( Fig. 1c and data not shown). This pattern was not present in normal plasma cells or in peripheral blood mononuclear cells (PBMCs) derived from healthy individuals 3 (Fig. 1a-c) , mirroring reports in other cellular contexts in which the presence of DNA damage discriminates normal tissues from preneoplastic and cancerous lesions 11, 12 . Notably, U266 and KMS-34 MM cell lines, which did not show γ-H2A.X foci, were also negative for all markers of DDR activation (Fig. 1c) . Surprisingly, despite this pervasive DNA damage and DDR activation, we did not detect any substantial cell death under basal conditions ( Fig. 1d and Supplementary Fig. 1c,d) , implying that MM cells have mechanisms to escape the apoptotic response triggered in normal cells.
ABL1 relocalization in the nucleus of MM cells As mentioned above, p53 genetic inactivation appears to be less relevant in hematopoietic neoplasms, including MM, than in epithelial cancers 4 . Indeed, modifications associated with DNA damage were present at a comparable level in both wild-type (WT) and p53-mutated MM cell lines ( Fig. 1c and data not shown). A second pathway involved in the apoptotic response after DSBs involves nuclear relocalization of ABL1 after DNA damage [7] [8] [9] [10] . We therefore asked whether ABL1 is localized in the nucleus in MM cells. Notably, ABL1 demonstrated a prominent and preferential localization inside the nucleus in most MM cells regardless of their p53 mutational status ( Fig. 1e) , which is in contrast to HeLa cells, where ABL1 shuttles inside the nucleus only after doxorubicin treatment (Supplementary Fig. 2a ).
Immunohistochemical staining also confirmed prominent nuclear ABL1 localization in cells derived from individuals with MM ( Fig. 1f and Supplementary Fig. 2b) .
After DNA damage, ATM is phosphorylated 13 . Moreover, activated JNK phosphorylates 14-3-3 proteins, leading to ABL1 release, which can in turn relocalize to the nucleus 14 . Indeed, treatment of MM cell lines with an ATM inhibitor, Ku55933 (ref. 15 ), or a JNK1 inhibitor, SP600125 (ref. 16 ), reduced nuclear and increased cytoplasmic ABL1 ( Fig. 2a,b and Supplementary Fig. 3a,b) in both WT and p53-mutant MM cell lines. Taken together, these results suggest that ongoing DNA damage in MM activates ATM and JNK, leading to nuclear relocalization of ABL1.
To determine whether nuclear ABL1 is able to induce apoptosis in MM cells, we used the U266 MM cell line, which does not show γ-H2A.X foci, pATM or nuclear ABL1 under basal conditions. Treatment with the DNA-damaging agent doxorubicin induced multiple γ-H2A.X foci and strong ATM and JNK phosphorylation ( Fig. 2c) . Notably, ABL1 moved into the nuclear compartment ( Fig. 2c) , and a marked increase in apoptotic cells was evident ( Fig. 2d) . Treatment with imatinib, an ABL1 kinase inhibitor, significantly (P < 0.001) increased viability, suggesting a prominent role for the kinase activity of nuclear ABL1 in inducing cell death in MM. An increase in γ-H2A.X, pATM and pJNK after exposure to doxorubicin was also evident in the MM.1S cell line, which presents DNA damage and DSBs in the basal state. These increases were associated with a major rise in nuclear ABL1 and apoptosis ( Supplementary  Fig. 3c-e ). However, in the presence of imatinib, cell viability significantly (P < 0.001) increased. In contrast, PBMCs isolated from healthy donors lacked ongoing DNA damage ( Fig. 1a,b Fig. 4a-d) .
We hence propose a model whereby MM cells live in a delicate equilibrium, withstanding high levels of persistent DNA damage that, through pATM and pJNK, leads to ABL1 nuclear relocalization, which should result in cell death. However, no apoptosis was evident in MM cells, suggesting that additional mechanisms are engaged in these cells to prevent their own demise.
YAP1 is deleted or consistently downregulated in MM cells ABL1 forms a complex with the tumor suppressor TP73 (p73), a p53 homolog 17 , and the Hippo pathway effector YAP1 (Yes-associated protein) 18, 19 . YAP1 and TAZ are the main transcriptional coactivators downstream of the Hippo pathway, controlling organ size and regulating stem and progenitor cell proliferation. In response to DNA damage, ABL1 induces apoptosis through YAP1 phosphorylation, which in turn stabilizes p73 and coactivates p73 proapoptotic target genes 19, 20 . Therefore, we sought to determine whether endogenous nuclear relocalization of ABL1 in MM is unable to induce apoptosis because of disruption of the ABL1-YAP1-p73 axis.
YAP1 behaves as an oncogene in several epithelial cancers. However, a detailed analysis of published gene expression profiling data sets revealed a noteworthy pattern: YAP1 was consistently upregulated in tumor cell lines of epithelial origin but was profoundly downregulated in hematologic malignancies, including lymphomas, leukemias and MM ( Fig. 3a) . Human YAP1 maps to chromosome 11 at the 11q22.1 locus, which is a site of focal homozygous deletions in 5-13% of MM samples [21] [22] [23] [24] . The genes implicated as targets of this deletion are BIRC2 and BIRC3, which control the pro-oncogenic nuclear factor κB (NF-κB) pathway 21, 22 . In reassessing previously published data by us and others 21, 23, 24 , we noticed that the deletion in this locus consistently involves YAP1 in addition to BIRC2 and BIRC3 in all MM cell lines and most primary MM samples that we analyzed (Fig. 3b) . At the gene expression level, probe sets reporting for YAP1 reflected low values overall, including in normal hematopoietic tissues. However, when we subdivided MM samples into two groups based on YAP1 expression, individuals with low expression had significantly shorter survival than those with high expression ( Fig. 3c) . Moreover, in various gene expression profiling data sets, there was a consistent, significant reduction in YAP1 expression levels, progressing from normal plasma cells to monoclonal gammopathy of undetermined significance to MM ( Fig. 3d and Supplementary 5a-c). Among MM cell lines, there are subsets presenting YAP1 homozygous deletions (KMS-18, KMS-20 and KMS-28PE), others with no detectable YAP1 at the mRNA or protein level despite no genomic losses at chromosome 11 and lines with robust expression of the gene (Fig. 3e,f and Supplementary Fig. 5d,e ).
YAP1 expression in MM cells induces ABL1-mediated apoptosis
We next explored the functional role of YAP1 in MM. In gain-offunction experiments, reintroduction of YAP1-eGFP (encoding enhanced GFP) 25 in deleted cell lines (KMS-18 and KMS-20) significantly reduced cell numbers and increased apoptosis (Fig. 4a,b and Supplementary Fig. 6a,b) . Conversely, downregulation of YAP1 with specific shRNAs in MM cell lines expressing YAP1 induced significant increases in proliferation and survival that were proportional to the reduction in YAP1 levels, whereas YAP1 overexpression did not affect cell count or apoptosis ( Fig. 4c and Supplementary Fig. 6c-f ).
As mentioned above, in a consistent number of MM cell lines that lack chromosome 11 deletion, YAP1 is not expressed. We therefore assessed whether reintroduction of YAP1 would affect cell proliferation and apoptosis in this specific MM subset as well. YAP1 overexpression in the MM.1S cell line markedly reduced proliferation and increased apoptosis to levels comparable to those in YAP1-deleted cells ( Fig. 4d and Supplementary Fig. 6g ). These results suggest that re-expression of YAP1 might induce apoptosis and reduce proliferation not only in MM cells in which YAP1 is deleted but also in the larger population of subjects with MM in which YAP1 is not expressed despite normal gene copy number. npg a r t i c l e s YAP1-induced apoptosis was mediated by nuclear ABL1 activity, as treatment with imatinib significantly reduced the apoptotic response, suggesting that YAP1 phosphorylation by ABL1 is required for the apoptotic response, as has been described previously 19 (Fig. 4e and Supplementary Fig. 7a ). Imatinib treatment also specifically reduced phosphorylation of YAP1 at Y357, which is required for the activation of proapoptotic genes mediated by YAP1 (ref. 19) ( Fig. 4e) . We obtained similar effects in the subset of MM cell lines with low YAP1 levels ( Supplementary Fig. 7a and data not shown). These results indicate that apoptosis induced by the nuclear relocalization of ABL1 in MM cells is prevented, at least in part, by low YAP1 levels. Because of the functional interaction between YAP1 and p73 (refs. 19,20,26,27) , we next explored the relationship between YAP1 and p73 after DNA damage in MM. Re-expression of YAP1 in the deleted MM cell lines markedly increased p73 protein levels with moderate effects on p73 mRNA levels, whereas p53 and TP63 (p63) protein levels were not altered ( Fig. 4f and Supplementary  Fig. 7b-d) . Accordingly, the levels of transcriptional p73 targets such as BAX, PUMA (also called BBC3) and CDKN1A (also called p21) significantly increased at both the mRNA and protein levels ( Fig. 4f,g) , whereas the levels of the p53 and p73 target NOXA did not vary.
ABL1-mediated phosphorylation of YAP1 at Y357 enhances its affinity toward p73 binding 28 . Indeed, imatinib treatment reduced the interaction of p73 with YAP1 ( Supplementary Fig. 7e ). To confirm the role of p73 in driving YAP1-mediated apoptosis, we transfected KMS-20 cells with a YAP1 mutant construct (dWW-YAP1) that lacks the WW domain that is necessary to interact with p73 (ref. 28 ). This mutant, unlike WT YAP1, was unable to trigger apoptosis and inhibit proliferation (Fig. 4h) . Taken together, these results suggest that apoptosis in MM induced by DNA damage and YAP1 restoration is mediated by stabilization of p73 and increased expression of its downstream proapoptotic targets.
Inactivation of kinase STK4 enhances YAP1 and apoptosis
A cytoplasmic serine-threonine kinase, STK4, interacts with another serine-threonine kinase, LATS1, and markedly reduces YAP1 levels 29, 30 . STK4 downregulation with specific shRNAs leads to a robust increase of YAP1 protein levels compared to scrambled shRNA (Fig. 5a) . Notably, YAP1 appeared in both the nucleus and cytoplasm after STK4 downregulation (Supplementary Fig. 8a) . We further explored whether STK4 downregulation affected YAP1 mRNA levels. A moderate increase in YAP1 mRNA levels was evident after STK4 inhibition (Supplementary Fig. 8b) . Of note, gene expression profiling data revealed a significant, inverse correlation between STK4 and YAP1 expression levels in MM samples (P < 0.0001; Supplementary Fig. 8c) . Fig. 8d ). Taken together, these results indicate that STK4 controls YAP1 at both the mRNA and protein levels.
Additionally, treatment of MM.1S cells with the proteasome inhibitor bortezomib robustly increased YAP1 protein levels (Supplementary
We then assessed whether upregulation of YAP1 induced by STK4 knockdown was associated with reduced proliferation. Indeed, all shRNAs that effectively downregulated STK4 expression and increased YAP1 levels also significantly inhibited MM cell proliferation ( Fig. 5b) and induced a robust apoptotic response ( Fig. 5c and Supplementary Fig. 9a ). We further confirmed this a r t i c l e s 6 0 4 VOLUME 20 | NUMBER 6 | JUNE 2014 nature medicine phenotype using an independent set of inducible shRNA sequences inserted into another vector or in different MM cell lines ( Fig. 5b and Supplementary Fig. 9b-e) .
Notably, treatment with bortezomib or doxorubicin enhanced this effect (Fig. 5c) . Additionally, inhibition of STK4 expression failed to reduce proliferation and increase apoptosis in the YAP1-deleted cell lines KMS-18 and KMS-20 ( Fig. 5d and Supplementary Fig. 10a,b) .
To further confirm that YAP1 mediates the phenotypes induced by STK4 inhibition, we concomitantly reduced the expression of STK4 and YAP1 in MM.1S cells with the respective shRNAs, which prevented apoptosis (Supplementary Fig. 10c) . These data demonstrate that the effects of STK4 inhibition in MM cells are mediated by restoration of YAP1. Expression of an STK4 mutant devoid of kinase activity, K59R 31 , in MM.1S and H929 MM cells downregulated for STK4 failed to repress YAP1 levels, rescue proliferation or prevent apoptosis, suggesting that STK4 kinase activity is required to suppress YAP1, thereby preventing apoptosis ( Fig. 5e and Supplementary Fig. 11a,b) .
These results indicate that YAP1 downregulation, seen in MM cells and cell lines in the absence of chromosome 11 deletion, can be due, at least in part, to the inhibitory effects of STK4 on YAP1 levels.
To demonstrate in vivo the relevance of this synthetically lethal interaction, we conditionally knocked down STK4 in MM.1S cells that were injected subcutaneously in mice fed with doxycycline in their drinking water to induce STK4 and scrambled silencing. Tumors developed exclusively from MM.1S cells infected with a scrambled shRNA, whereas no growth was evident in STK4-silenced cells (P < 0.0001; Fig. 5f ). Taken together, our results demonstrate that STK4 inhibition upregulates YAP1 levels in MM cells, thereby triggering apoptosis both in vitro and in vivo (Fig. 5g) .
DNA damage, ABL1, STK4 and YAP1 in lymphoma and leukemia
We next assessed DNA damage in a panel of lymphoma, lymphoblastic and myeloid leukemias and Waldenström macroglobulinemia cell lines. Staining with γ-H2A.X revealed robust, ongoing DNA damage in the majority of the cell lines assessed (Fig. 6a,b) . Moreover, consistent nuclear localization of ABL1 was evident ( Fig. 6c and Supplementary  Fig. 12a) . YAP1 mRNA and protein levels were low, similarly to in MM cells ( Fig. 6d and Supplementary Fig. 12b ). Remarkably, as in MM, cells derived from individuals with leukemia showing low YAP1 expression had a significantly worse prognosis (Fig. 6e) . The reintroduction of YAP1 in acute lymphoblastic leukemia (ALL) (Jurkat) or AML (OCI/AML3) ( Fig. 6f,g) was associated with apoptosis and induction of p73 target genes ( Fig. 6f-h and Supplementary Fig. 13 ). As in MM, STK4 reduction through STK4 shRNAs increased YAP1 levels, reduced cell numbers and enhanced apoptosis ( Fig. 6i and Supplementary Fig. 14) .
DISCUSSION
In this study we demonstrated that MM, lymphomas and leukemias present pervasive DNA damage. As a result, the proapoptotic tyrosine kinase ABL1 relocalizes to the nucleus, uncovering an unexpected broad role for this protein in inducing apoptosis during the DDR.
Tumor cells nevertheless escape apoptosis as a result of genetic inactivation or reduced expression of the Hippo co-transcription factor YAP1. We elucidate a new synthetic-lethal approach 32 in which inhibition of the kinase STK4 reactivates YAP1 and triggers ABL1dependent apoptosis, providing the rationale for developing STK4 inhibitors for clinical evaluation in hematological malignancies. As in neoplasms of epithelial origin 1 , activation of the DNA damage checkpoint might also be a barrier against the evolution toward cancer in hematological tissues; however, unlike epithelial cancers, hematological malignancies do not seem to require p53 inactivation.
Instead, early inactivation of the ABL1-YAP1-p73 axis may substitute for p53 mutations and/or inactivation in hematological tumors.
YAP1 is focally amplified in a vast array of solid tumors, including brain, colon and hepatocellular carcinomas, and has been reported consistently as an oncogene in epithelial cancers 33 . Our data support a role for YAP1 as a tumor-suppressor gene in hematological cancers. A possible explanation for this differential function may relate to YAP1 forming complexes with various partners with distinct functional sequelae, depending on the cellular context 34 . For example, in the absence of DNA damage, YAP1 preferentially interacts with the oncogenic transcription modulator RUNX, leading to increased degradation of p73 (ref. 20) . Thus, transcription modulators can shift YAP1 away from p73 toward other partners, endowing YAP1 with proliferative and anti-apoptotic features.
The heart of the Hippo pathway includes a core of two serinethreonine kinase pairs, STK4 (also called MST1) and STK3 (also called MST2), which activate two other kinases, LATS1 and LATS2. In turn, LATS1 and LATS2 regulate YAP1 and the other Hippo mediator, TAZ 35 . The concomitant loss of both STK4 and STK3 is required to foster the development of hepatocellular carcinoma in vivo 29 . In our a r t i c l e s 6 0 6 VOLUME 20 | NUMBER 6 | JUNE 2014 nature medicine study, the STK4-specific shRNAs used did not affect STK3 mRNA levels ( Supplementary Fig. 15 ), suggesting that STK4 exerts a prominent, specific role in controlling YAP1 levels in MM. As for other Hippo pathway members, recent intriguing findings have implicated LATS2 in DNA damage and cell cycle control 36, 37 , suggesting that the Hippo pathway exerts a tight control on DNA damage and reinforcing the notion of a tumor-suppressive role for this pathway in specific contexts such as hematological cancers. YAP1 presents a high degree of sequence homology with TAZ. Although they often have overlapping functions, the two proteins seem to exert independent roles, as exemplified by the phenotypes of the mouse knockouts and the specific functions of TAZ in stem cell maintenance and WNT regulation 38 . Unlike YAP1, we did not detect focal deletions affecting the TAZ locus in MM cell lines and in cells derived from individuals with MM, suggesting that tumors of hematological lineage preferentially inactivate YAP1.
Kinases are valuable targets for cancer therapies, as has been shown with imatinib, erlotinib and gefitinib. Therefore, STK4 provides a promising therapeutic target in hematological cancers displaying low YAP1 levels and concomitant DNA damage. Notably, STK4 knockdown induced apoptosis in both WT and p53-mutant cells, suggesting that restoring YAP1 levels could be a new treatment strategy even in tumors with p53 inactivation and poor prognosis.
METHODS
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